goniothalamin profile

goniothalamin: has antineoplastic activity; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6440856
CHEMBL ID	464443
SCHEMBL ID	12444498
MeSH ID	M0270104

Synonym
(6r)-(+)-goniothalamin
goniothalamine
ccris 9005
2h-pyran-2-one, 5,6-dihydro-6-(2-phenylethenyl)-, (s-(e))-
2h-pyran-2-one, 5,6-dihydro-6-styryl-, (5s)-(+)-
nsc-104956
goniothalamin
styryldihydropyran
22639-28-7
(r)-(+)-goniothalamin
CHEMBL464443
(r)-goniothalamin
(2r)-2-[(e)-2-phenylethenyl]-2,3-dihydropyran-6-one
34w9go6b2z ,
17303-67-2
unii-34w9go6b2z
(6r)-6.alpha.-((e)-styryl)-5,6-dihydro-2h-pyran-2-one
(2r)-2-[(e)-styryl]-2,3-dihydropyran-6-one
SCHEMBL12444498
AKOS032948430
FS-9350
Q27256393
(6r)-6-[(1e)-2-phenylethenyl]-5,6-dihydro-2h-pyran-2-one
CS-0024535
HY-N3968
2h-pyran-2-one, 5,6-dihydro-6-[(e)-2-phenylethenyl]-, (6r)-
DTXSID801035678

Excerpt	Reference	Relevance
"(R)-Goniothalamin, is a member of styryl lactones, possesses selective cytotoxicity against cancer cell lines. "	( 6-Bicycloaryl substituted (S)- and (R)-5,6-dihydro-2H-pyran-2-ones: asymmetric synthesis, and anti-proliferative properties. Cağir, A; Kasaplar, P; Yilmazer, O, 2009)	0.91
"Goniothalamin (GTN) is a natural compound isolated from Goniothalamus species. "	( Goniothalamin prevents lipopolysaccharide-induced acute lung injury and inflammation via TLR-4/NF-κB signaling pathway. Gao, L; Hu, Z; Li, L; Ma, Z; Zhou, Y; Zou, G, 2023)	3.8
"(R)-Goniothalamin (R-GNT) is a secondary metabolite isolated from the plants of the genus Goniothalamus. "	( (S)-Goniothalamin induces DNA damage, apoptosis, and decrease in BIRC5 messenger RNA levels in NCI-H460 cells. de Fátima, Â; Lepri, SR; Mantovani, MS; Ribeiro, LR; Sartori, D; Semprebon, SC, 2014)	1.52
"Goniothalamin is a biologically active styrylpyrone derivative isolated from various Goniothalamus species. "	( Goniothalamin selectively induces apoptosis on human hepatoblastoma cells through caspase-3 activation. Al-Qubaisi, M; Ali, AM; Alitheen, NB; Omar, AR; Rosli, R; Subramani, T; Yeap, SK, 2013)	3.28
"Goniothalamin is an active compound extracted from Goniothalamus griffithii, a local plant found in northern Thailand. "	( Apoptosis induction in human leukemic promyelocytic HL-60 and monocytic U937 cell lines by goniothalamin. Banjerdpongchai, R; Petsophonsakul, P; Pompimon, W, 2013)	2.05
"Goniothalamin is a natural product that has been demonstrated to induce apoptosis in various cancer cell lines."	( Involvement of Seladin-1 in goniothalamin-induced apoptosis in urinary bladder cancer cells. Din, LB; Fauzi, AR; Inayat-Hussain, SH; McKelvey-Martin, VJ; Meng, CK; Rajab, NF; Yen, HK, 2014)	1.42
"(R)-goniothalamin (R-GNT) is a styryl lactone that exhibits antiproliferative property against several tumor cell lines. "	( Antiproliferative activity of goniothalamin enantiomers involves DNA damage, cell cycle arrest and apoptosis induction in MCF-7 and HB4a cells. D'Epiro, GF; da Silva, GN; de Camargo, EA; Macedo Junior, F; Mantovani, MS; Marques, LA; Niwa, AM; Semprebon, SC, 2015)	1.26
"Goniothalamin is a natural occurring styryl-lactone compound isolated from Goniothalamus macrophyllus. "	( Goniothalamin induces cell cycle arrest and apoptosis in H400 human oral squamous cell carcinoma: A caspase-dependent mitochondrial-mediated pathway with downregulation of NF-κβ. Alabsi, AM; Ali, AM; Kaid, FA; Li, LK; Rola, AS, 2016)	3.32
"Goniothalamin is a styryllactone synthesized by plants of the genus Goniothalamus. "	( Cytotoxicity of goniothalamin enantiomers in renal cancer cells: involvement of nitric oxide, apoptosis and autophagy. de Carvalho, JE; de Fátima, A; Ferreira, CV; Gadelha, FR; Hyslop, S; Modolo, LV; Pilli, RA; Salgado, I; Tarsitano, CA; Zambuzzi, WF, 2008)	2.13
"Goniothalamin oxide (1) is a styryl lactone which was isolated from bark and leaves of several Goniothalamus species. "	( Asymmetric total synthesis and antiproliferative activity of goniothalamin oxide isomers. de Carvalho, JE; de Fátima, A; Kohn, LK; Marquissolo, C; Pilli, RA; Ruiz, AL, 2009)	2.04
"Goniothalamin (GTN) is a styrylpyrrone derivative from Goniothalamus umbrosus and other Annonaceae species. "	( Genotoxicity of goniothalamin in CHO cell line. Din, LB; Lai, LC; Mohamed-Said, MS; Rosli, R; Umar-Tsafe, N, 2004)	2.11

Excerpt	Reference	Relevance
"Goniothalamin treatment of cells significantly induced cell cycle arrest at G(2)/M phase and apoptosis."	( Goniothalamin induces cell cycle-specific apoptosis by modulating the redox status in MDA-MB-231 cells. Chang, FR; Chen, WY; Lan, YH; Teng, CM; Wu, CC; Wu, YC, 2005)	2.49

Excerpt	Reference	Relevance
" The study findings showed that antimalarial property of goniothalamin was enhanced by combination with chloroquine at lower dose of each drug."	( Antimalarial properties of Goniothalamin in combination with chloroquine against Plasmodium yoelii and Plasmodium berghei growth in mice. Khozirah, S; Mohd Ridzuan, MA; Noor Rain, A; Ruenruetai, U; Zakiah, I, 2006)	0.88

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)	IC50 (µMol)	7.0000	0.0001	1.9731	8.0000	AID1142307
Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)	IC50 (µMol)	7.0000	0.0001	1.8088	8.0000	AID1142307
Transcription factor p65	Homo sapiens (human)	IC50 (µMol)	7.0000	0.0001	1.8981	8.8000	AID1142307
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to lipopolysaccharide	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
apoptotic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
inflammatory response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
canonical NF-kappaB signal transduction	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
JNK cascade	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of gene expression	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of lipid storage	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of calcidiol 1-monooxygenase activity	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of vitamin D biosynthetic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of cholesterol transport	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of interleukin-12 production	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
response to muscle stretch	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of apoptotic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of inflammatory response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
B cell receptor signaling pathway	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
negative regulation of protein metabolic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
mammary gland involution	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of transcription initiation by RNA polymerase II	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to mechanical stimulus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to nicotine	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to interleukin-1	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to interleukin-6	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to tumor necrosis factor	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to dsRNA	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to interleukin-17	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to virus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
antibacterial innate immune response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of hyaluronan biosynthetic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to angiotensin	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
positive regulation of miRNA metabolic process	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cellular response to stress	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
innate immune response	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
response to cytokine	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
follicular dendritic cell differentiation	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
germinal center formation	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
regulation of DNA-templated transcription	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
canonical NF-kappaB signal transduction	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
extracellular matrix organization	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
response to lipopolysaccharide	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
rhythmic process	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
spleen development	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
cellular response to stress	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
innate immune response	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
response to cytokine	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
inflammatory response	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-6 production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-8 production	Transcription factor p65	Homo sapiens (human)
positive regulation of amyloid-beta formation	Transcription factor p65	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Transcription factor p65	Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathway	Transcription factor p65	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Transcription factor p65	Homo sapiens (human)
liver development	Transcription factor p65	Homo sapiens (human)
hair follicle development	Transcription factor p65	Homo sapiens (human)
defense response to tumor cell	Transcription factor p65	Homo sapiens (human)
response to ischemia	Transcription factor p65	Homo sapiens (human)
acetaldehyde metabolic process	Transcription factor p65	Homo sapiens (human)
chromatin organization	Transcription factor p65	Homo sapiens (human)
DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
regulation of DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Transcription factor p65	Homo sapiens (human)
inflammatory response	Transcription factor p65	Homo sapiens (human)
cellular defense response	Transcription factor p65	Homo sapiens (human)
neuropeptide signaling pathway	Transcription factor p65	Homo sapiens (human)
canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
positive regulation of cell population proliferation	Transcription factor p65	Homo sapiens (human)
response to xenobiotic stimulus	Transcription factor p65	Homo sapiens (human)
animal organ morphogenesis	Transcription factor p65	Homo sapiens (human)
response to UV-B	Transcription factor p65	Homo sapiens (human)
positive regulation of vascular endothelial growth factor production	Transcription factor p65	Homo sapiens (human)
positive regulation of gene expression	Transcription factor p65	Homo sapiens (human)
positive regulation of Schwann cell differentiation	Transcription factor p65	Homo sapiens (human)
negative regulation of angiogenesis	Transcription factor p65	Homo sapiens (human)
cytokine-mediated signaling pathway	Transcription factor p65	Homo sapiens (human)
protein catabolic process	Transcription factor p65	Homo sapiens (human)
response to muramyl dipeptide	Transcription factor p65	Homo sapiens (human)
response to progesterone	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-12 production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-6 production	Transcription factor p65	Homo sapiens (human)
positive regulation of interleukin-8 production	Transcription factor p65	Homo sapiens (human)
response to insulin	Transcription factor p65	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Transcription factor p65	Homo sapiens (human)
negative regulation of protein sumoylation	Transcription factor p65	Homo sapiens (human)
response to cobalamin	Transcription factor p65	Homo sapiens (human)
toll-like receptor 4 signaling pathway	Transcription factor p65	Homo sapiens (human)
intracellular signal transduction	Transcription factor p65	Homo sapiens (human)
cellular response to hepatocyte growth factor stimulus	Transcription factor p65	Homo sapiens (human)
response to muscle stretch	Transcription factor p65	Homo sapiens (human)
non-canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Transcription factor p65	Homo sapiens (human)
prolactin signaling pathway	Transcription factor p65	Homo sapiens (human)
negative regulation of protein catabolic process	Transcription factor p65	Homo sapiens (human)
negative regulation of apoptotic process	Transcription factor p65	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
response to amino acid	Transcription factor p65	Homo sapiens (human)
negative regulation of DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
positive regulation of DNA-templated transcription	Transcription factor p65	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Transcription factor p65	Homo sapiens (human)
negative regulation of insulin receptor signaling pathway	Transcription factor p65	Homo sapiens (human)
regulation of inflammatory response	Transcription factor p65	Homo sapiens (human)
positive regulation of T cell receptor signaling pathway	Transcription factor p65	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Transcription factor p65	Homo sapiens (human)
response to cAMP	Transcription factor p65	Homo sapiens (human)
defense response to virus	Transcription factor p65	Homo sapiens (human)
cellular response to hydrogen peroxide	Transcription factor p65	Homo sapiens (human)
interleukin-1-mediated signaling pathway	Transcription factor p65	Homo sapiens (human)
response to interleukin-1	Transcription factor p65	Homo sapiens (human)
cellular response to lipopolysaccharide	Transcription factor p65	Homo sapiens (human)
cellular response to lipoteichoic acid	Transcription factor p65	Homo sapiens (human)
cellular response to peptidoglycan	Transcription factor p65	Homo sapiens (human)
cellular response to nicotine	Transcription factor p65	Homo sapiens (human)
cellular response to interleukin-1	Transcription factor p65	Homo sapiens (human)
cellular response to interleukin-6	Transcription factor p65	Homo sapiens (human)
cellular response to tumor necrosis factor	Transcription factor p65	Homo sapiens (human)
postsynapse to nucleus signaling pathway	Transcription factor p65	Homo sapiens (human)
antiviral innate immune response	Transcription factor p65	Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Transcription factor p65	Homo sapiens (human)
negative regulation of miRNA transcription	Transcription factor p65	Homo sapiens (human)
positive regulation of miRNA transcription	Transcription factor p65	Homo sapiens (human)
cellular response to angiotensin	Transcription factor p65	Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cell	Transcription factor p65	Homo sapiens (human)
positive regulation of miRNA metabolic process	Transcription factor p65	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Transcription factor p65	Homo sapiens (human)
cellular response to stress	Transcription factor p65	Homo sapiens (human)
response to cytokine	Transcription factor p65	Homo sapiens (human)
innate immune response	Transcription factor p65	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
chromatin binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
transcription coregulator activity	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
protein binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
identical protein binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
actinin binding	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
protein binding	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
transcription cis-regulatory region binding	Transcription factor p65	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Transcription factor p65	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Transcription factor p65	Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Transcription factor p65	Homo sapiens (human)
transcription coactivator binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Transcription factor p65	Homo sapiens (human)
DNA binding	Transcription factor p65	Homo sapiens (human)
chromatin binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription factor activity	Transcription factor p65	Homo sapiens (human)
protein binding	Transcription factor p65	Homo sapiens (human)
enzyme binding	Transcription factor p65	Homo sapiens (human)
protein kinase binding	Transcription factor p65	Homo sapiens (human)
chromatin DNA binding	Transcription factor p65	Homo sapiens (human)
ubiquitin protein ligase binding	Transcription factor p65	Homo sapiens (human)
peptide binding	Transcription factor p65	Homo sapiens (human)
phosphate ion binding	Transcription factor p65	Homo sapiens (human)
identical protein binding	Transcription factor p65	Homo sapiens (human)
protein homodimerization activity	Transcription factor p65	Homo sapiens (human)
actinin binding	Transcription factor p65	Homo sapiens (human)
histone deacetylase binding	Transcription factor p65	Homo sapiens (human)
NF-kappaB binding	Transcription factor p65	Homo sapiens (human)
ankyrin repeat binding	Transcription factor p65	Homo sapiens (human)
general transcription initiation factor binding	Transcription factor p65	Homo sapiens (human)
DNA-binding transcription factor binding	Transcription factor p65	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
nucleus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
nucleoplasm	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cytoplasm	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
mitochondrion	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cytosol	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
secretory granule lumen	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
specific granule lumen	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
chromatin	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
transcription regulator complex	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
I-kappaB/NF-kappaB complex	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
nucleus	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
cytoplasm	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
NF-kappaB p50/p65 complex	Nuclear factor NF-kappa-B p105 subunit	Homo sapiens (human)
nucleus	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
nucleoplasm	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
cytoplasm	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
cytosol	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
chromatin	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
Bcl3/NF-kappaB2 complex	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
cytoplasm	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
nucleus	Nuclear factor NF-kappa-B p100 subunit	Homo sapiens (human)
nucleolus	Transcription factor p65	Homo sapiens (human)
nucleus	Transcription factor p65	Homo sapiens (human)
glutamatergic synapse	Transcription factor p65	Homo sapiens (human)
nucleus	Transcription factor p65	Homo sapiens (human)
nucleoplasm	Transcription factor p65	Homo sapiens (human)
cytoplasm	Transcription factor p65	Homo sapiens (human)
cytosol	Transcription factor p65	Homo sapiens (human)
NF-kappaB p50/p65 complex	Transcription factor p65	Homo sapiens (human)
NF-kappaB complex	Transcription factor p65	Homo sapiens (human)
chromatin	Transcription factor p65	Homo sapiens (human)
transcription regulator complex	Transcription factor p65	Homo sapiens (human)
cytoplasm	Transcription factor p65	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (88)

Assay ID	Title	Year	Journal	Article
AID490148	Cytotoxicity against mouse P388 cells	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Synthesis and cytotoxic activity of fluorinated analogues of Goniothalamus lactones. Impact of fluorine on oxidative processes.
AID1168771	Induction of apoptosis in human PANC1 cells assessed as increase in BAX/BCL-2 ratio at 30 to 60 uM after 24 hrs by Western blot analysis	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID764830	Antiproliferative activity against human 786-0 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Design, synthesis and in vitro evaluation against human cancer cells of 5-methyl-5-styryl-2,5-dihydrofuran-2-ones, a new series of goniothalamin analogues.
AID478311	Induction of apoptosis in human MDA-MB-231 cells	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport.
AID764833	Antiproliferative activity against human U251 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Design, synthesis and in vitro evaluation against human cancer cells of 5-methyl-5-styryl-2,5-dihydrofuran-2-ones, a new series of goniothalamin analogues.
AID410511	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	2009	Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1	6-Bicycloaryl substituted (S)- and (R)-5,6-dihydro-2H-pyran-2-ones: asymmetric synthesis, and anti-proliferative properties.
AID490149	Cytotoxicity against mouse WEHI164 cells	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Synthesis and cytotoxic activity of fluorinated analogues of Goniothalamus lactones. Impact of fluorine on oxidative processes.
AID764827	Antiproliferative activity against human HT-29 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Design, synthesis and in vitro evaluation against human cancer cells of 5-methyl-5-styryl-2,5-dihydrofuran-2-ones, a new series of goniothalamin analogues.
AID510201	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID1168769	Effect on AXL in human PANC1 cells assessed as increase in p-ERK at Thr202/Tyr 204 protein level at 30 to 60 uM after 24 hrs by Western blot analysis	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID510204	Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID1564020	Induction of apoptosis in human 3D HepG2 spheroids measured after 24 hrs by propidium iodide staining based immunofluorescence microscopy analysis
AID490151	Cytotoxicity against human MDA-MB-231 cells	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Synthesis and cytotoxic activity of fluorinated analogues of Goniothalamus lactones. Impact of fluorine on oxidative processes.
AID1168773	Induction of apoptosis in human PANC1 cells assessed as reduction in pro-caspase-3 level at 30 to 60 uM after 24 hrs by Western blot analysis	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID764834	Antiproliferative activity against human UACC62 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Design, synthesis and in vitro evaluation against human cancer cells of 5-methyl-5-styryl-2,5-dihydrofuran-2-ones, a new series of goniothalamin analogues.
AID490150	Cytotoxicity against human Hep3B cells	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Synthesis and cytotoxic activity of fluorinated analogues of Goniothalamus lactones. Impact of fluorine on oxidative processes.
AID663994	Growth inhibition of human OVCAR3 cells after 48 hrs by sulforhodamine B assay	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Synthesis of methoxylated goniothalamin, aza-goniothalamin and γ-pyrones and their in vitro evaluation against human cancer cells.
AID1460693	Inhibition of Pdr5 ATPase activity in Saccharomyces cerevisiae YRE1001 plasma membranes assessed as residual activity at 500 ug/ml after 20 mins in presence of ATP by colorimetric assay relative to control	2017	Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22	Synthesis and cytotoxic activities of goniothalamins and derivatives.
AID1460694	Inhibition of Pdr5 ATPase activity in Saccharomyces cerevisiae YRE1001 plasma membranes assessed as residual activity at 50 ug/ml after 20 mins in presence of ATP by colorimetric assay relative to control	2017	Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22	Synthesis and cytotoxic activities of goniothalamins and derivatives.
AID1168762	Reduction in p-RB at Ser795 protein level in human PANC1 cells at 30 to 60 uM after 24 hrs by Western blot analysis	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID1460691	Antiproliferative activity against human HBL100 cells after 48 hrs by CellTiter-Glo luminescent cell viability assay	2017	Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22	Synthesis and cytotoxic activities of goniothalamins and derivatives.
AID482108	Inhibition of CRM1-mediated nuclear export of Rio2 in human HeLa cells at 1 uM	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport.
AID663991	Growth inhibition of human NCI/ADR cells after 48 hrs by sulforhodamine B assay	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Synthesis of methoxylated goniothalamin, aza-goniothalamin and γ-pyrones and their in vitro evaluation against human cancer cells.
AID1487693	Inhibition of CRM1-mediated nucleocytoplasmic transport of Riok2 in human HeLa cells at 5 uM after 6 hrs by DAPI staining based microscopy	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	CRM1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives.
AID764826	Antiproliferative activity against human HaCaT cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Design, synthesis and in vitro evaluation against human cancer cells of 5-methyl-5-styryl-2,5-dihydrofuran-2-ones, a new series of goniothalamin analogues.
AID1487707	Cytotoxicity against human HuH7 cell spheroids assessed as cell death at 50 uM after 72 hrs by propidium staining based fluorescence microscopy relative to control	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	CRM1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives.
AID510202	Cytotoxicity against human NCI-ADR-RES cells after 48 hrs by sulforhodamine B assay	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID510210	Acute toxicity in BALB/C mouse assessed as mortality at up to 300 mg/kg, ip after 15 days	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID1168750	Cytotoxicity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID756435	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	(+)-Altholactone exhibits broad spectrum immune modulating activity by inhibiting the activation of pro-inflammatory cytokines in RAW 264.7 cell lines.
AID410513	Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay	2009	Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1	6-Bicycloaryl substituted (S)- and (R)-5,6-dihydro-2H-pyran-2-ones: asymmetric synthesis, and anti-proliferative properties.
AID1168780	Chemical reactivity under non-physiological condition at 25 mM using gluthatione as thiol nucleophile assessed as conjugate addition of GSH to compound after 24 hrs by 1H NMR spectroscopy	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID1168753	Cytoprotective activity in 1 hr GSH-pretreated human PANC1 cells assessed as increase in cell viability at 10 to 100 uM after 24 hrs by MTT reduction assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID1460689	Antiproliferative activity against human A549 cells after 48 hrs by CellTiter-Glo luminescent cell viability assay	2017	Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22	Synthesis and cytotoxic activities of goniothalamins and derivatives.
AID1168777	Induction of intracellular ROS production in human PANC1 cells at 1.5 to 3 uM after 1 hr using DCFH-DA by flow cytometry	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID1168758	Antiproliferative activity against human PANC1 cells assessed as reduction in colonies at 30 uM after 15 days by colony assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID410512	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	2009	Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1	6-Bicycloaryl substituted (S)- and (R)-5,6-dihydro-2H-pyran-2-ones: asymmetric synthesis, and anti-proliferative properties.
AID510227	Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as reduction of tumor weight at 50 mg/kg, ip administered every 3 days measured on day 15 relative to control	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID1564030	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 to 72 hrs
AID1168752	Selectivity ratio of IC50 for human HaCaT cells to IC50 for human PANC1 cells	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID1487692	Inhibition of CRM1-mediated nucleocytoplasmic transport of Riok2 in human HeLa cells at 5 uM after 90 mins by DAPI staining based microscopy relative to control	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	CRM1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives.
AID1168757	Antiproliferative activity against human PANC1 cells assessed as reduction in colonies at 15 uM after 15 days by colony assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID510200	Cytotoxicity against human UACC62 cells after 48 hrs by sulforhodamine B assay	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID478310	Cytotoxicity against human MDA-MB-231 cells	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport.
AID410514	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	2009	Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1	6-Bicycloaryl substituted (S)- and (R)-5,6-dihydro-2H-pyran-2-ones: asymmetric synthesis, and anti-proliferative properties.
AID1487697	Inhibition of CRM1-mediated nucleocytoplasmic transport of Riok2 in human HeLa cells at 0.5 uM after 90 mins by DAPI staining based microscopy relative to control	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	CRM1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives.
AID1564007	Cytotoxicity against human HepG2 cells assessed as growth inhibition
AID510230	Acute toxicity in BALB/C mouse assessed as reduction of body weight at up to 50 mg/kg, ip after 15 days	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID764828	Antiproliferative activity against human K562 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Design, synthesis and in vitro evaluation against human cancer cells of 5-methyl-5-styryl-2,5-dihydrofuran-2-ones, a new series of goniothalamin analogues.
AID756436	Cytotoxicity against mouse RAW264.7 cells after 18 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	(+)-Altholactone exhibits broad spectrum immune modulating activity by inhibiting the activation of pro-inflammatory cytokines in RAW 264.7 cell lines.
AID510205	Cytotoxicity against human PCO3 cells after 48 hrs by sulforhodamine B assay	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID1460696	Inhibition of Pdr5 in Saccharomyces cerevisiae YRE1001 plasma membranes assessed as reduction in rhodamine 6G transport by measuring relative fluorescence intensity at 500 ug/ml preincubated with enzyme followed by ATP addition measured for 20 mins by flu	2017	Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22	Synthesis and cytotoxic activities of goniothalamins and derivatives.
AID1168761	Reduction in c-Myc protein level in human PANC1 cells at 30 to 60 uM after 24 hrs by Western blot analysis	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID663996	Growth inhibition of human HaCaT cells after 48 hrs by sulforhodamine B assay	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Synthesis of methoxylated goniothalamin, aza-goniothalamin and γ-pyrones and their in vitro evaluation against human cancer cells.
AID1168775	Induction of apoptosis in human PANC1 cells assessed as increase in cleaved PARP-1 level at 30 to 60 uM after 24 hrs by Western blot analysis	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID764829	Antiproliferative activity against human PC3 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Design, synthesis and in vitro evaluation against human cancer cells of 5-methyl-5-styryl-2,5-dihydrofuran-2-ones, a new series of goniothalamin analogues.
AID764832	Antiproliferative activity against human MCF7 cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Design, synthesis and in vitro evaluation against human cancer cells of 5-methyl-5-styryl-2,5-dihydrofuran-2-ones, a new series of goniothalamin analogues.
AID510206	Cytotoxicity against human OVCAR-3 cells after 48 hrs by sulforhodamine B assay	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID1487691	Inhibition of CRM1-mediated nucleocytoplasmic transport of Riok2 in human HeLa cells at 1 uM after 90 mins by DAPI staining based microscopy relative to control	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	CRM1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives.
AID510209	Acute toxicity in BALB/C mouse assessed as mortality at up to 300 mg/kg, ip after 4 hrs	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID510208	Cytotoxicity against human U251 cells after 48 hrs by sulforhodamine B assay	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID1168760	Reduction in cyclin D1 protein level in human PANC1 cells at 30 to 60 uM after 24 hrs by Western blot analysis	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID1460700	Inhibition of Pdr5 in Saccharomyces cerevisiae YRE1001 plasma membranes assessed as reduction in rhodamine 6G transport by measuring relative fluorescence intensity at 50 ug/ml preincubated with enzyme followed by ATP addition measured for 20 mins by fluo	2017	Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22	Synthesis and cytotoxic activities of goniothalamins and derivatives.
AID1487706	Cytotoxicity against human HuH7 cell spheroids assessed as cell death at 50 uM after 24 hrs by propidium staining based fluorescence microscopy relative to control	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	CRM1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives.
AID1168759	Antiproliferative activity against human PANC1 cells assessed as reduction in colonies after 15 days by colony assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID510224	Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as inhibition of increase in tumor volume at 50 mg/kg, ip administered every 3 days measured on day 13 relative to control	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID1460692	Cytotoxicity against Saccharomyces cerevisiae YRE1001 up to 100 ug/ml after 48 hrs by liquid drug assay	2017	Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22	Synthesis and cytotoxic activities of goniothalamins and derivatives.
AID510203	Cytotoxicity against human 786-0 cells after 48 hrs by sulforhodamine B assay	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID663995	Growth inhibition of human HT-29 cells after 48 hrs by sulforhodamine B assay	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Synthesis of methoxylated goniothalamin, aza-goniothalamin and γ-pyrones and their in vitro evaluation against human cancer cells.
AID663992	Growth inhibition of human 786-0 cells after 48 hrs by sulforhodamine B assay	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Synthesis of methoxylated goniothalamin, aza-goniothalamin and γ-pyrones and their in vitro evaluation against human cancer cells.
AID663989	Growth inhibition of human U251 cells after 48 hrs by sulforhodamine B assay	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Synthesis of methoxylated goniothalamin, aza-goniothalamin and γ-pyrones and their in vitro evaluation against human cancer cells.
AID1168751	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 24 hrs by MTT reduction assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID756434	Inhibition of LPS-induced NF-kappaB activation in mouse RAW264.7 cells after 18 hrs by luciferase assay	2013	Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14	(+)-Altholactone exhibits broad spectrum immune modulating activity by inhibiting the activation of pro-inflammatory cytokines in RAW 264.7 cell lines.
AID1460701	Inhibition of Pdr5 in Saccharomyces cerevisiae YRE1001 plasma membranes assessed as reduction in rhodamine 6G transport by measuring relative fluorescence intensity at 5 ug/ml preincubated with enzyme followed by ATP addition measured for 20 mins by fluor	2017	Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22	Synthesis and cytotoxic activities of goniothalamins and derivatives.
AID510223	Antitumor activity against mouse EAC cells xenografted in BALB/C mouse assessed as inhibition of increase in tumor volume at 50 mg/kg, ip administered every 3 days measured on day 15 relative to control	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID510207	Cytotoxicity against human HT-29 cells after 48 hrs by sulforhodamine B assay	2010	Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18	Effect of goniothalamin on the development of Ehrlich solid tumor in mice.
AID663993	Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Synthesis of methoxylated goniothalamin, aza-goniothalamin and γ-pyrones and their in vitro evaluation against human cancer cells.
AID663990	Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Synthesis of methoxylated goniothalamin, aza-goniothalamin and γ-pyrones and their in vitro evaluation against human cancer cells.
AID764831	Antiproliferative activity against human NCI-ADR-RES cells assessed as concentration required for total cell growth inhibition after 48 hrs by SRB assay	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Design, synthesis and in vitro evaluation against human cancer cells of 5-methyl-5-styryl-2,5-dihydrofuran-2-ones, a new series of goniothalamin analogues.
AID1487698	Inhibition of CRM1-mediated nucleocytoplasmic transport of Riok2 in human HeLa cells at 0.1 uM after 90 mins by DAPI staining based microscopy relative to control	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	CRM1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives.
AID1564008	Cytotoxicity against human Hep3B cells assessed as growth inhibition
AID1460690	Antiproliferative activity against human MCF7 cells after 48 hrs by CellTiter-Glo luminescent cell viability assay	2017	Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22	Synthesis and cytotoxic activities of goniothalamins and derivatives.
AID1460695	Inhibition of Pdr5 ATPase activity in Saccharomyces cerevisiae YRE1001 plasma membranes assessed as residual activity at 5 ug/ml after 20 mins in presence of ATP by colorimetric assay relative to control	2017	Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22	Synthesis and cytotoxic activities of goniothalamins and derivatives.
AID490144	Cytotoxicity against human MCF7 cells after 24 hrs	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Synthesis and cytotoxic activity of fluorinated analogues of Goniothalamus lactones. Impact of fluorine on oxidative processes.
AID1142307	Inhibition of NF-kappaB transactivation in TNF-alpha-stimulated human K562 cells preincubated for 2 hrs followed by TNF-alpha challenge measured after 6 hrs by dual luciferase reporter gene assay	2014	Bioorganic & medicinal chemistry, Jun-01, Volume: 22, Issue:11	Bis(4-hydroxy-2H-chromen-2-one): synthesis and effects on leukemic cell lines proliferation and NF-κB regulation.
AID1168767	Reduction in AXL protein level in human PANC1 cells at 30 to 60 uM after 24 hrs by Western blot analysis	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A new goniothalamin N-acylated aza-derivative strongly downregulates mediators of signaling transduction associated with pancreatic cancer aggressiveness.
AID1487694	Inhibition of CRM1-mediated nucleocytoplasmic transport of Riok2 in human HeLa cells at 0.2 uM after 90 mins by DAPI staining based microscopy relative to control	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	CRM1 inhibitory and antiproliferative activities of novel 4'-alkyl substituted klavuzon derivatives.
AID490146	Cytotoxicity against human HepG2 cells after 24 hrs	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Synthesis and cytotoxic activity of fluorinated analogues of Goniothalamus lactones. Impact of fluorine on oxidative processes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (3.75)	18.2507
2000's	16 (20.00)	29.6817
2010's	55 (68.75)	24.3611
2020's	6 (7.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (2.47%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	79 (97.53%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.02	1	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
benzamide benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.	2.07	1	benzamides
celecoxib [no description available]	2.84	3	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	7.03	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.05	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	7.1	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
mimosine Mimosine: 3-Hydroxy-4-oxo-1(4H)-pyridinealanine. An antineoplastic alanine-substituted pyridine derivative isolated from Leucena glauca.	2.02	1	alpha-amino acid
beta-lapachone beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.	2.1	1	benzochromenone; orthoquinones	anti-inflammatory agent; antineoplastic agent; plant metabolite
nocodazole [no description available]	2.02	1	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
phloretin [no description available]	2.1	1	dihydrochalcones	antineoplastic agent; plant metabolite
sanguinarine benzophenanthridine alkaloid : A specific group of isoquinoline alkaloids that occur only in higher plants and are constituents mainly of the Papaveraceae family.	2.1	1	alkaloid antibiotic; benzophenanthridine alkaloid; botanical anti-fungal agent
thymidine [no description available]	2.02	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.03	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
ethanethiol ethanethiol: RN given refers to parent cpd; structure. ethanethiol : An alkanethiol that is ethane substituted by a thiol group at position 1. It is added to odorless gaseous products such as liquefied petroleum gas (LPG) to provide a garlic scent which helps warn of gas leaks.	2.05	1	alkanethiol	rodenticide
diphenyl diphenyl: RN given refers to unlabeled cpd; structure	2.31	1	aromatic fungicide; benzenes; biphenyls	antifungal agrochemical; antimicrobial food preservative
furan furan : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing four carbons and one oxygen, with formula C4H4O. It is a toxic, flammable, low-boiling (31degreeC) colourless liquid.	7.08	1	furans; mancude organic heteromonocyclic parent; monocyclic heteroarene	carcinogenic agent; hepatotoxic agent; Maillard reaction product
thiazoles [no description available]	2.46	2	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
liriodenine liriodenine: structure given in first source. liriodenine : An oxoaporphine alkaloid that is 4,5,6,6a-tetradehydronoraporphin-7-one substituted by a methylenedioxy group across positions 1 and 2. It is isolated from Annona glabra and has been shown to exhibit antimicrobial and cytotoxic activities.	2.07	1	alkaloid antibiotic; cyclic ketone; organic heteropentacyclic compound; oxacycle; oxoaporphine alkaloid	antifungal agent; antimicrobial agent; antineoplastic agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; metabolite
trinitrobenzenesulfonic acid Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.	2.13	1	arenesulfonic acid; C-nitro compound	epitope; explosive; reagent
2-piperidone 2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.	2.31	1	delta-lactam; piperidones	EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
buthionine sulfoximine Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.	2.02	1	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
chromium Chromium: A trace element that plays a role in glucose metabolism. It has the atomic symbol Cr, atomic number 24, and atomic weight 52. According to the Fourth Annual Report on Carcinogens (NTP85-002,1985), chromium and some of its compounds have been listed as known carcinogens.. chromium ion : An chromium atom having a net electric charge.. chromium atom : A chromium group element atom that has atomic number 24.	2.05	1	chromium group element atom; metal allergen	micronutrient
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.15	1	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
fluorine Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.	2.05	1	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
azoxymethane Azoxymethane: A potent carcinogen and neurotoxic compound. It is particularly effective in inducing colon carcinomas.	2.15	1
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	2.1	1	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.46	2	organic bromide salt	colorimetric reagent; dye
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.31	1	1,2,3-triazole
pinocembrin pinocembrin : A dihydroxyflavanone in which the two hydroxy groups are located at positions 5 and 7. A natural product found in Piper sarmentosum and Cryptocarya chartacea.	2.13	1	(2S)-flavan-4-one; dihydroxyflavanone	antineoplastic agent; antioxidant; metabolite; neuroprotective agent; vasodilator agent
isobutyramide [no description available]	2.21	1	carboximidic acid
3-chloroperbenzoic acid 3-chloroperbenzoic acid: oxidizing agent	2.05	1	monochlorobenzenes; peroxy acid
altersolanol a altersolanol A: isolated from fermentation product of fungus Alternaria porri(Ellis) Ciferri;RN given refers to (1R-(1alpha,2beta,3beta,4alpha))-isomer; structure given in first source	2.1	1	pentahydroxyanthraquinone
proximadiol proximadiol: dicyclic sesquiterpenediol from Cymbopogon proximus with antispasmodic activity	2.07	1	eudesmane sesquiterpenoid	metabolite
goniodiol goniodiol: from Malaysian medicinal plant; structure in first source	2.45	2
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	2.31	1
altholactone altholactone: structure in first source	2.48	2	furopyran
e-z cinnamic acid cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia.. trans-cinnamic acid : The E (trans) isomer of cinnamic acid	2.07	1	cinnamic acid	plant metabolite
piplartine piplartine: Antineoplastic Agent, Phytogenic; alkaloid from Piper; structure in first source	7.57	2	cinnamamides; dicarboximide
isoliquiritigenin [no description available]	2.1	1	chalcones	antineoplastic agent; biological pigment; EC 1.14.18.1 (tyrosinase) inhibitor; GABA modulator; geroprotector; metabolite; NMDA receptor antagonist
sesquiterpenes [no description available]	2.07	1
pterodondiol pterodondiol: anti-bacterial from Laggera pterodonta; structure in first source	2.07	1	eudesmane sesquiterpenoid
5,6-dehydrokawain 5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source	2.21	1	2-pyranones; aromatic ether
butein [no description available]	2.1	1	chalcones; polyphenol	antineoplastic agent; antioxidant; EC 1.1.1.21 (aldehyde reductase) inhibitor; geroprotector; hypoglycemic agent; plant metabolite; radiosensitizing agent; tyrosine kinase inhibitor
yangonin yangonin: structure in first source	2.21	1	2-pyranones; aromatic ether
4-hydroxychalcone 4-hydroxychalcone: structure in first source. 4-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 4.	2.1	1	chalcones; phenols	antihypertensive agent; plant metabolite
flavokawain C flavokawain C: antineoplastic from roots of Kava (Piper methysticum Forst); structure in first source	2.1	1	chalcones
3-o-methylbutein 3-O-methylbutein: RN given refers to (E)-isomer; structure given in first source	2.1	1	chalcones
howiinol a howiinol A: isolated from Goniothalamus howii; structure in first source; do not confuse with GHM-10, gas hypoxic mixture of 90% N2 & 10% O2	2.05	1
mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).	2.13	1	aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline	antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent
dihydrokavain dihydrokavain: inhibits binding of batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltage-gated sodium channels	2.21	1	2-pyranones; aromatic ether
lemonomycin lemonomycin: structure in first source	2.05	1
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.97	4
interleukin-8 Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.	2.08	1
piroxicam [no description available]	2.05	1	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.31	1	benzenes; hydroxycoumarin; methyl ketone
4-hydroxycoumarin 2-hydroxychromone: structure	2.1	1	hydroxycoumarin
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor	2.42	2

Condition	Relationship Strength	Studies
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	2.48	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.8	3
Anasarca [description not available]	2.48	2
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.48	2
Innate Inflammatory Response [description not available]	3.25	5
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	8.25	5
Cancer of Pancreas [description not available]	2.1	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.1	1
Breast Cancer [description not available]	3.61	8
Breast Neoplasms Tumors or cancer of the human BREAST.	3.61	8
Lung Injury, Acute [description not available]	2.6	1
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	7.6	1
Adenocarcinoma, Basal Cell [description not available]	2.55	2
Cancer of Prostate [description not available]	3.03	4
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.55	2
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	3.03	4
Invasiveness, Neoplasm [description not available]	2.17	1
Benign Neoplasms [description not available]	3.92	4
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.92	4
Carcinoma, Non-Small Cell Lung [description not available]	2.48	2
Cancer of Lung [description not available]	2.48	2
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.48	2
Lung Neoplasms Tumors or cancer of the LUNG.	2.48	2
Cancer of Liver [description not available]	2.76	3
Liver Neoplasms Tumors or cancer of the LIVER.	2.76	3
Hepatoblastoma A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)	2.48	2
Acute Promyelocytic Leukemia [description not available]	2.08	1
Diffuse Large B-Cell Lymphoma [description not available]	2.08	1
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	2.08	1
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	2.08	1
Leucocythaemia [description not available]	2.08	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.08	1
Bladder Cancer [description not available]	7.1	1
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.1	1
Gastric Ulcer [description not available]	2.1	1
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	2.1	1
Ache [description not available]	2.11	1
Primary Peritonitis [description not available]	2.11	1
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.11	1
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	2.11	1
Colorectal Cancer [description not available]	2.81	3
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.81	3
Carcinoma, Squamous Cell of Head and Neck [description not available]	2.13	1
Carcinoma, Epidermoid [description not available]	2.5	2
Cancer of Head [description not available]	2.13	1
Cancer of Mouth [description not available]	2.5	2
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	2.13	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.5	2
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.13	1
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.5	2
Cancer of Colon [description not available]	2.5	2
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.54	2
Colonic Neoplasms Tumors or cancer of the COLON.	2.5	2
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	2.15	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	7.15	1
Cancer of Kidney [description not available]	2.44	2
Kidney Neoplasms Tumors or cancers of the KIDNEY.	2.44	2
Hepatocellular Carcinoma [description not available]	7.06	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.06	1
Parasitemia The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)	2.03	1
Infections, Plasmodium [description not available]	2.03	1
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	7.03	1
Weight Gain Increase in BODY WEIGHT over existing weight.	2.04	1

goniothalamin

Description

Cross-References

Synonyms (27)

Research Excerpts

Overview

Treatment

Compound-Compound Interactions

Protein Targets (3)

Inhibition Measurements

Biological Processes (107)

Molecular Functions (28)

Ceullar Components (16)

Bioassays (88)

Research

Studies (80)

Market Indicators

Research Demand Index: 22.63

Study Types

goniothalamin

Description

Cross-References

Synonyms (27)

Research Excerpts

Overview

Treatment

Compound-Compound Interactions

Protein Targets (3)

Inhibition Measurements

Biological Processes (107)

Molecular Functions (28)

Ceullar Components (16)

Bioassays (88)

Research

Studies (80)

Market Indicators

Research Demand Index: 22.63

Study Types

Related Drugs (57)

Related Conditions (63)